Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Saurin Rajnikant Popat

University of Buffalo School of Medicine & Dentistry, USA

Title: Use of Induction Chemotherapy for Advanced Stage Oral Cavity Squamous Cell Carcinoma

Biography

Biography: Saurin Rajnikant Popat

Abstract

Abstrcat:

Oral cavity  squamous cell carcinoma (OC-SCCa) accounts for  nearly 1/3 of all head and neck squamous cell cancers in the US however with significant international geographic variation due to carcinogen exposure and availability. The mainstay of treatment for resectable disease had been surgery with postoperative radiation based on specific clinical and pathologic features.   Survival rates have little improved prior to the use of concurrent postoperative chemoradition.   Since 2009, we have employed induction chemotherapy (ICT)  as an option to be added to the comprehensive treatment of OC-SCCa. A review of our outcomes was conducted.

Patients/Methods:  Retrospective review from 2010 -2015 of  patients with stage IV OC-SCCa with minimal 24 month follow-up who received  ICT and with no previous history of treated head & neck SCCa.  59 patients were identified however 6 met inclusion criteria.  All received 2 to 3 cycles of ICT consisting of cisplatin and either fluorouracil and/or a taxane.  Following IHC, all underwent surgical resection.

Results: Survival from OC-SCCa was 100% with 4 patients NED and 2 patients DOC/NED.  Median survival was 54.3 months.  Three patients had ICT complications but recovered and proceeded to surgery.  There were 3 surgical complications in 2 patients.  Historic literature based on AJCC data has survial at 4.5 years to be approximately 29%.

Conclusions: Though the study size is small, ICT demonstrated excellent tumor response in our patient population with enduring and superior disease free survival.  A larger multicenter trial would be required to confirm these results and outline chemotherapy drug selection.